$0.83
1.80% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US22978P1066
Symbol
CUE

Cue Biopharma, Inc. Stock price

$0.83
-0.07 8.12% 1M
-0.44 34.96% 6M
-0.26 24.22% YTD
+0.01 1.34% 1Y
-2.22 72.92% 3Y
-17.76 95.56% 5Y
-10.80 92.90% 10Y
-10.80 92.90% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.01 1.80%
ISIN
US22978P1066
Symbol
CUE
Industry

Key metrics

Basic
Market capitalization
$63.5m
Enterprise Value
$38.6m
Net debt
positive
Cash
$27.5m
Shares outstanding
76.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.7 | 7.8
EV/Sales
4.7 | 4.7
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
54.4%
Return on Equity
-232.4%
ROCE
-183.5%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$8.3m | $8.2m
EBITDA
$-39.0m | -
EBIT
$-39.4m | $-39.4m
Net Income
$-38.9m | $-45.6m
Free Cash Flow
$-28.3m
Growth (TTM | estimate)
Revenue
-0.1% | -12.2%
EBITDA
18.6% | -
EBIT
18.5% | 5.3%
Net Income
17.2% | -12.0%
Free Cash Flow
26.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-470.4% | -
EBIT
-475.2%
Net
-469.4% | -558.6%
Free Cash Flow
-341.7%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
1.2%
Employees
41
Rev per Employee
$230.0k
Show more

Is Cue Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Cue Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cue Biopharma, Inc. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Cue Biopharma, Inc. forecast:

Buy
83%
Hold
17%

Financial data from Cue Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
8.29 8.29
0% 0%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
8% 8%
178%
- Research and Development Expense 33 33
18% 18%
398%
-39 -39
19% 19%
-470%
- Depreciation and Amortization 0.40 0.40
9% 9%
5%
EBIT (Operating Income) EBIT -39 -39
18% 18%
-475%
Net Profit -39 -39
17% 17%
-469%

In millions USD.

Don't miss a Thing! We will send you all news about Cue Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cue Biopharma, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held i...
Neutral
GlobeNewsWire
11 days ago
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, announced today the initiation of an investigator sponsored trial (IST) in rGBM at the DFCI with the first patient ...
Neutral
GlobeNewsWire
11 days ago
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided a business and financial update for the second quarter 2025.
More Cue Biopharma, Inc. News

Company Profile

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Daniel Passeri
Employees 41
Founded 2014
Website www.cuebiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today